
Another week dominated by COVID-19. Among our most popular stories this week, Celltrion’s infliximab biosimilar Remsima has scored approval for …

Japan’s Ministry of Health, Labour and Welfare (MHLW) has sealed a deal with Pfizer and BioNTech to secure 120 million …

Janssen’s IL-12 and IL-23 inhibitor Stelara (ustekinumab) has had its approved indications expanded by the FDA to include the treatment …

NICE has revealed that a combination of Merck KGaA’s Bavencio (avelumab) and Pfizer’s Inlyta (axitinib) will be made available as …

Boehringer Ingelheim and Eli Lilly have announced strong Phase 3 news on their sodium-glucose co-transporter-2 (SGLT2) inhibitor Jardiance (empagliflozin) in …

Sanofi’s nirsevimab met its goals in a Phase 2b study, the company has revealed, investigating its efficacy in the prevention …

UCB Pharma is set to partner up with Roche and Genentech in a development and commercialisation deal focused on its …

While the company has more recently drawn headlines for its COVID-19 efforts, BioNTech has unveiled promising interim Phase 1 data …

NICE has issued draft guidance that has shot down Kyowa Kirin’s therapy Poteligeo (mogamulizumab) for use on the NHS in …

Japan’s biggest drug firm Takeda is said to be mulling plans to cut back its sales operations with a new …

The once-touted COVID cure hydroxychloroquine continues its downward spiral of credibility as new data is published on its lack of …

The European Commission (EC) has awarded its approval for Novartis’ Piqray (alpelisib) to be made available in combination with fulvestrant …

The UK Government has sealed another deal to procure an effective COVID-19 vaccine for its citizens, partnering up with Sanofi …

Roche has announced the disappointing news that its therapy Actemra/RoActemra (tocilizumab) failed to improve clinical status to a statistically significant …

Eli Lilly Shanghai, an affiliate of the wider company, has enlisted the help of biopharma firm Hutchinson China MediTech, or …

Biopharma firm AI Therapeutics is partnering with Yale School of Medicine to launch a new clinical trial to identify the efficacy …

AstraZeneca has teased new data from a Phase 3 study of its sodium-glucose co-transporter-2 (SGLT2) inhibitor Farxiga (dapagliflozin) in the …

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has given its backing to Kyowa Kirin’s …

The subcutaneous (SC) formulation of Remsima, Celltrion’s biosimilar version of infliximab, has secured approval from the European Commission covering five …

AstraZeneca and Daiichi Sankyo have joined forces to drive the development and commercialisation of the latter’s DS-1062, a trophoblast cell-surface …